Focus on osteoporosis, osteoarthritis and sarcopenia at largest congress in the field
The International Osteoporosis Foundation (IOF) and the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO) will welcome more than 4000 delegates to the WCO-IOF-ESCEO 2018, opening today in Kraków, Poland. The CME-accredited Congress is the world's largest gathering of clinicians and researchers working in the field of musculoskeletal disorders.
"We look forward to an outstanding Congress which will give delegates information about advances in patient care, insights into the latest clinical research, and excellent opportunities for international networking," said Professor Jean-Yves Reginster, Congress co-chair and President of ESCEO.
He added, "The year-to-year increase in delegate numbers and submitted abstracts reflects the growing interest in musculoskeletal disorders, the second greatest cause of disability worldwide. Disorders such as osteoporosis, osteoarthritis, and sarcopenia represent an enormous and rapidly growing human and socioeconomic burden. Given the urgent need for action to stem the tide of disability and early death due to these serious disorders, it is crucial that we, as practitioners and researchers, stay continually abreast of the latest advances in the field."
The Congress will feature 10 plenary lectures by leading experts in the bone field, including P. Conaghan, C. Cooper, P. Ebeling, S. Ferrari, P. Hadji, F. Landi, E. McCloskey, M. McClung, R. Rizzoli, and T. Thomas. Furthermore, four Special Lectures, 13 Meet-the-Expert Sessions, seven ESCEO Symposia, 29 Non-Sponsored Symposia, and six Industry-Sponsored Symposia, will focus on the latest advances within a wide range of important topics. These include global dietary intake of calcium, bone fragility in diabetes and breast cancer, sarcopenia and frailty, FRAX, bone microstructure, treatments, osteoarthritis management, inflammation and musculoskeletal ageing, microbiota and bone disease, obesity and fracture risk, among many other topics.
Oral and poster presentations from more than 1500 submitted abstracts will showcase the latest research in the field. The abstracts have been published in the scientific journal 'Osteoporosis International', Volume 29, Supplement 1, 2018.
IOF Honorary President and Congress Co-Chair Prof. John A. Kanis, stated: "This Congress will move the field one step forward on all fronts by highlighting the latest developments in a broad range of areas – from bone metabolism and pathology, to new strategies and options in the prevention, diagnosis and treatment of disorders such as sarcopenia and frailty."
With the closing of the Congress in Krakow on Sunday March 22, planning will begin for next year's World Congress, which will take place in Paris, France from April 4-7, 2019.
World Congress on Osteoporosis, Osteoarthritis & Musculoskeletal Diseases (WCO-IOF-ESCEO Kraków 2018)
Held jointly by IOF and ESCEO, the Congress takes place in Kraków, Poland, from April 19-22, 2018. WCO-IOF-ESCEO is the world's largest annual forum for the presentation of clinical research and new advances in the prevention and management of musculoskeletal disorders, including sarcopenia and frailty. For complete information visit http://www.wco-iof-esceo.org #OsteoCongress
The International Osteoporosis Foundation (IOF) is the world's largest nongovernmental organization dedicated to the prevention, diagnosis and treatment of osteoporosis and related musculoskeletal diseases. IOF members, including committees of scientific researchers as well as 240 patient, medical and research societies in 99 locations, work together to make fracture prevention and healthy mobility a worldwide heath care priority. http://www.iofbonehealth.org http://www.facebook.com/ @iofbonehealth
The European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO) is a non-profit organization, dedicated to a close interaction between clinical scientists dealing with rheumatic disorders, pharmaceutical industry developing new compounds in this field, regulators responsible for the registration of such drugs and health policy makers, to integrate the management of osteoporosis and osteoarthritis within the comprehensive perspective of health resources utilization. The objective of ESCEO is to provide practitioners with the latest clinical and economic information, allowing them to organize their daily practice, in an evidence-based medicine perspective, with a cost-conscious perception. http://www.esceo.org